Can PVP Labs turn Taphalgin into a battlefield alternative to scheduled opioids?
PVP Labs will present Taphalgin at MHSRS 2026 as a battlefield pain candidate, but U.S. trials and FDA review remain decisive.
Pharma & Biotech
Pharma & Biotech
DEA targets enhanced 7-OH products with proposed Schedule I controls
Read how DEA’s proposed Schedule I controls for enhanced 7-OH could reshape kratom products, enforcement and research in the United States.
Pharma & Biotech
Parnell expands U.S. manufacturing footprint with Noble Pharma acquisition amid supply continuity pressures
Parnell’s Noble Pharma acquisition expands U.S. veterinary drug manufacturing capacity. Read what it could change for supply, scale, and market strategy.